Compass Therapeutics, Inc.
CMPXDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Aug 10, 2026
5dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
CMPX Earnings Report
EPS Est: $-0.10 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How CMPX's past catalysts played out
CTX-009
Metastatic Colorectal Cancer
Paclitaxel
Biliary Tract Cancer
Psilocybin
Post Traumatic Stress Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CTX-009 | Phase 3 | Metastatic Colorectal Cancer | - | - |
Paclitaxel | Phase 3 | Biliary Tract Cancer | - | - |
Psilocybin | Phase 3 | Post Traumatic Stress Disorder | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Compass Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Compass Therapeutics, Inc.'s (CMPX) pipeline across Phase 3. Its lead program is CTX-009 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Compass Therapeutics, Inc.'s next FDA catalyst?→
Compass Therapeutics, Inc.'s (CMPX) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CMPX biotech catalysts?→
Add CMPX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Compass Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.